Literature DB >> 6275990

Biochemical activation of AZQ [3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone] to its free radical species.

P L Gutierrez, R D Friedman, N R Bachur.   

Abstract

The aziridinyl quinone 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone is an antitumor agent that enhances electron flow from reduced nicotinamide adenine dinucleotide phosphate (NADPH) to molecular oxygen in rat liver microsomes, rat liver nuclei, and purified NADPH-cytochrome c reductase. The process is enzymatic and has an optimum pH of 7.5; NADPH is the preferred cofactor. Electron spin resonance studies show the presence of a free radical semiquinone characterized by five hyperfine lines at g = 2.0046.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6275990

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  7 in total

Review 1.  Diaziquone (AZQ).

Authors:  J F Bender; A J Grillo-Lopez; J G Posada
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

2.  Response variability of human brain tumors to AZQ in tissue culture.

Authors:  P L Kornblith; L Rosa; J D Bona; J A Edwards; N Matuzic; A Hirschfeld; C Hawkins
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

Review 3.  Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?

Authors:  J Butler; B M Hoey
Journal:  Br J Cancer Suppl       Date:  1987-06

4.  Thiol oxidation coupled to DT-diaphorase-catalysed reduction of diaziquone. Reductive and oxidative pathways of diaziquone semiquinone modulated by glutathione and superoxide dismutase.

Authors:  I D Ordoñez; E Cadenas
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

5.  A phase II trial of diaziquone in patients with head and neck cancer.

Authors:  F Muñiz; E Vélez-García; J A Neidhart; J F Bender; M Becker; A J Grillo-Lopez
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.

Authors:  M C Chamberlain; M D Prados; P Silver; V A Levin
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130

7.  Activities of free radical metabolizing enzymes in tumours.

Authors:  M J Tisdale; M B Mahmoud
Journal:  Br J Cancer       Date:  1983-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.